Lauren F Sestito
Overview
Explore the profile of Lauren F Sestito including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Camargo C, Muhuri A, Alapan Y, Sestito L, Khosla M, Manspeaker M, et al.
Cell Rep
. 2023 Feb;
42(3):112175.
PMID: 36848287
CD8 T cell recruitment to the tumor microenvironment is critical for the success of adoptive cell therapy (ACT). Unfortunately, only a small fraction of transferred cells home to solid tumors....
2.
Sestito L, To K, Cribb M, Archer P, Thomas S, Dixon J
Sci Adv
. 2023 Feb;
9(8):eabq0435.
PMID: 36827374
Dysfunction of collecting lymphatic vessel pumping is associated with an array of pathologies. S-(-)-Bay K8644 (BayK), a small-molecule agonist of L-type calcium channels, improves vessel contractility ex vivo but has...
3.
Kim J, Francis D, Sestito L, Archer P, Manspeaker M, OMelia M, et al.
Nat Commun
. 2022 Mar;
13(1):1479.
PMID: 35304456
Due to their autosynchronous roles in shaping the anti-tumor immune response, complex immune regulatory networks acting both locally within the tumor microenvironment as well as in its draining lymph nodes...
4.
Francis D, Manspeaker M, Archer P, Sestito L, Heiler A, Schudel A, et al.
Biomaterials
. 2021 Oct;
279:121184.
PMID: 34678650
Multiple small molecule immune modulators have been identified as synergistic with immune checkpoint blockade (ICB) in their effects on T lymphocytes, but are limited in their successful application to combination...
5.
Archer P, Sestito L, Manspeaker M, OMelia M, Rohner N, Schudel A, et al.
Drug Deliv Transl Res
. 2021 Jun;
11(6):2328-2343.
PMID: 34165731
Lymph nodes (LNs) are tissues of the immune system that house leukocytes, making them targets of interest for a variety of therapeutic immunomodulation applications. However, achieving accumulation of a therapeutic...
6.
Cribb M, Sestito L, Rockson S, Nicolls M, Thomas S, Dixon J
Int J Mol Sci
. 2021 Apr;
22(9).
PMID: 33923272
The mechanisms of lymphedema development are not well understood, but emerging evidence highlights the crucial role the immune system plays in driving its progression. It is well known that lymphatic...
7.
Sestito L, Thomas S
Biomaterials
. 2020 Oct;
265:120411.
PMID: 33080460
Lymph nodes (LNs) are immune organs housing high concentrations of lymphocytes, making them critical targets for therapeutic immunomodulation in a wide variety of diseases. While there is great interest in...
8.
Kim J, Sestito L, Im S, Kim W, Thomas S
Adv Funct Mater
. 2020 Oct;
30(16).
PMID: 33071710
Despite the approval of oncolytic virus therapy for advanced melanoma, its intrinsic limitations that include the risk of persistent viral infection and cost-intensive manufacturing motivate the development of analogous approaches...
9.
Francis D, Manspeaker M, Schudel A, Sestito L, OMelia M, Kissick H, et al.
Sci Transl Med
. 2020 Oct;
12(563).
PMID: 32998971
Systemic administration of immune checkpoint blockade (ICB) monoclonal antibodies (mAbs) can unleash antitumor functions of T cells but is associated with variable response rates and off-target toxicities. We hypothesized that...
10.
Sestito L, Thomas S
ACS Pharmacol Transl Sci
. 2020 Apr;
2(5):293-310.
PMID: 32259064
Immunoengineering is a rapidly growing and interdisciplinary field focused on developing tools to study and understand the immune system, then employing that knowledge to modulate immune response for the treatment...